BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the US FDA Approval as 1L Treatment for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shots:
- The approvals were based on the P-III (CheckMate -648) trial evaluating Opdivo + Yervoy or Opdivo + CT vs CT alone in adult patients with prior untreated unresectable advanced, recurrent, or metastatic ESCC
- The results showed that Opdivo + Yervoy or Opdivo + CT improved OS in all randomized & tumors express PD-L1 (≥1%) patients. In both patients with Opdivo + CT, m-OS (13.2mos. & 15.4mos. vs 10.7mos. & 9.1mos.); m-PFS (5.8mos. & 6.9mos. vs 5.6mos. & 4.4mos.)
- Opdivo + Yervoy showed m-OS (12.8mos. & 13.7mos. vs 10.7mos. & 9.1 mos.) in both patients; m-PFS (4.0mos. vs 4.4mos.) in tumors express PD-L1 (≥1%) patients, patients discontinued treatment in Opdivo + Yervoy or Opdivo + CT (23% & 39%)
Ref: BMS | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
